Finance

Lists
Why is 4142 down 6.62%?
Dive Deeper
4142:TPE
Adimmune Corp
NT$14.80
-6.62%
(-1.05) 1D
ኖቬም 20, 1:30:09 ከሰዓት ጂ ኤም ቲ+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 4142...
Open
NT$15.75
High
NT$15.75
Low
NT$14.80
Mkt. cap
6.36 ቢ
Avg. vol.
1.13 ሚ
Volume
1.63 ሚ
P/E ratio
85.76
52-wk high
NT$21.50
52-wk low
NT$14.80
EPS
NT$0.17
Shares outstanding
235.29 ሚ
No. of employees
564
Open
NT$15.75
High
NT$15.75
Low
NT$14.80
Mkt. cap
6.36 ቢ
Avg. vol.
1.13 ሚ
Volume
1.63 ሚ
P/E ratio
85.76
52-wk high
NT$21.50
52-wk low
NT$14.80
EPS
NT$0.17
Shares outstanding
235.29 ሚ
No. of employees
564
News stories
From web sources and news partners
Adam Feldman | Substack
Adam Feldman | Substack
·
ከ1 ቀን በፊት
Inside the Federal Litigation of Five S&P 500 Giants
Investor's Business Daily
Investor's Business Daily
·
ከ38 ደቂቃዎች በፊት
This VIX Signal Is Bullish For The S&P 500.
Yahoo Finance
Yahoo Finance
·
ከ7 ሰዓቶች በፊት
SPDR S&P 500 ETF (SPY) Sells Apple and Microsoft on Nov. 18
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets. Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026. Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations. In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease. In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022. In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
ዲሴም 2025
ማርች 2026
ጁን 2026
ሴፕቴ 2026
Revenue
745.46 ሚ
82.32 ሚ
66.76 ሚ
715.67 ሚ
Cost of goods sold
376.00 ሚ
156.87 ሚ
129.59 ሚ
413.47 ሚ
Cost of revenue
376.00 ሚ
156.87 ሚ
129.59 ሚ
413.47 ሚ
Research and development expenses
74.68 ሚ
45.44 ሚ
30.55 ሚ
27.96 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
94.80 ሚ
79.22 ሚ
79.34 ሚ
84.37 ሚ
Operating expense
197.18 ሚ
124.66 ሚ
109.88 ሚ
112.33 ሚ
Total operating expenses
573.18 ሚ
281.54 ሚ
239.47 ሚ
525.80 ሚ
Operating income
172.28 ሚ
-199.22 ሚ
-172.71 ሚ
189.87 ሚ
Other non operating income
10.40 ሚ
710.00 ሺ
2.18 ሚ
2.03 ሚ
EBT including unusual items
200.77 ሚ
-200.47 ሚ
-172.95 ሚ
185.53 ሚ
EBT excluding unusual items
200.30 ሚ
-198.95 ሚ
-172.95 ሚ
185.53 ሚ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
220.42 ሚ
-185.54 ሚ
-160.23 ሚ
198.10 ሚ
Net profit margin
29.57%
-225.41%
-240.02%
27.68%
Earnings per share
-
-
-
0.47
Interest and investment income
9.92 ሚ
3.10 ሚ
6.47 ሚ
3.04 ሚ
Interest expense
-10.40 ሚ
-7.40 ሚ
-6.95 ሚ
-9.42 ሚ
Net interest expenses
-475.00 ሺ
-4.30 ሚ
-480.00 ሺ
-6.38 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
219.90 ሚ
-156.74 ሚ
-128.36 ሚ
266.40 ሚ
Gain or loss from assets sale
-3.00 ሺ
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች